MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 563589 | Name: EGFR-IN-557

Description:

WARNING: This product is for research use only, not for human or veterinary use.

EGFR-IN-557 is an EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis.

Chemical Structure

EGFR-IN-557
EGFR-IN-557
CAS#1639040-91-7

Theoretical Analysis

MedKoo Cat#: 563589

Name: EGFR-IN-557

CAS#: 1639040-91-7

Chemical Formula: C26H20FN5O

Exact Mass: 437.1652

Molecular Weight: 437.47

Elemental Analysis: C, 71.38; H, 4.61; F, 4.34; N, 16.01; O, 3.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
EGFR-IN-557; EGFRIN557; EGFR IN 557; EGFR inhibitor 557; EGFR-inhibitor-557;
IUPAC/Chemical Name
N-{4-[1-(3-Fluoro-benzyl)-1H-indol-5-ylamino]-quinazolin-6-yl}-acrylamide
InChi Key
CWFVSHJUGHKLMO-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H20FN5O/c1-2-25(33)30-21-6-8-23-22(14-21)26(29-16-28-23)31-20-7-9-24-18(13-20)10-11-32(24)15-17-4-3-5-19(27)12-17/h2-14,16H,1,15H2,(H,30,33)(H,28,29,31)
SMILES Code
C=CC(NC1=CC2=C(NC3=CC4=C(N(CC5=CC=CC(F)=C5)C=C4)C=C3)N=CN=C2C=C1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 437.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ou Y, Wu Q, Wu C, Liu X, Song Y, Zhan Q. Migfilin promotes migration and invasion in glioma by driving EGFR and MMP-2 signalings: A positive feedback loop regulation. J Genet Genomics. 2017 Dec 20;44(12):557-565. doi: 10.1016/j.jgg.2017.09.008. Epub 2017 Oct 16. PubMed PMID: 29203120. 2: Wang J, Bai H, Hong C, Wang J, Mei TH. Analyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day. Thorac Cancer. 2017 Jul;8(4):312-319. doi: 10.1111/1759-7714.12443. Epub 2017 Apr 24. Erratum in: Thorac Cancer. 2017 Nov;8(6):741. PubMed PMID: 28437026; PubMed Central PMCID: PMC5494457. 3: Azan A, Caspers PJ, Bakker Schut TC, Roy S, Boutros C, Mateus C, Routier E, Besse B, Planchard D, Seck A, Kamsu Kom N, Tomasic G, Koljenović S, Noordhoek Hegt V, Texier M, Lanoy E, Eggermont AM, Paci A, Robert C, Puppels GJ, Mir LM. A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. Cancer Res. 2017 Jan 15;77(2):557-565. doi: 10.1158/0008-5472.CAN-16-1733. Epub 2016 Nov 11. PubMed PMID: 27836854. 4: Li J, Hong Q, Zhang X, Hu J, Bai C. [Therapeutic efficacy and safety of chemotherapy subsequent EGFR-TKI in advanced non-small cell lung cancer patients with EGFR-TKI acquired resistance]. Zhonghua Yi Xue Za Zhi. 2014 Aug 13;94(30):2342-5. Chinese. PubMed PMID: 25399974. 5: Yang X, Yang K, Kuang K. The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review. Curr Oncol Rep. 2014 Jun;16(6):390. doi: 10.1007/s11912-014-0390-4. Review. PubMed PMID: 24807015. 6: Qin N, Yang X, Zhang Q, Li X, Zhang H, Lv J, Wu Y, Wang J, Zhang S. Efficacy of Icotinib treatment in patients with stage IIIb/IV non-small cell lung cancer. Thorac Cancer. 2014 May;5(3):243-9. doi: 10.1111/1759-7714.12085. Epub 2014 Apr 22. PubMed PMID: 26767007; PubMed Central PMCID: PMC4704301. 7: Nakayama A, Takagi S, Yusa T, Yaguchi M, Hayashi A, Tamura T, Kawakita Y, Ishikawa T, Ohta Y. Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model. J Cancer. 2013 Aug 16;4(7):557-65. doi: 10.7150/jca.6689. eCollection 2013. PubMed PMID: 23983820; PubMed Central PMCID: PMC3753530. 8: Frosi Y, Anastasi S, Ballarò C, Varsano G, Castellani L, Maspero E, Polo S, Alemà S, Segatto O. A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. J Cell Biol. 2010 May 3;189(3):557-71. doi: 10.1083/jcb.201002032. Epub 2010 Apr 26. PubMed PMID: 20421427; PubMed Central PMCID: PMC2867293. 9: Jaramillo ML, Banville M, Collins C, Paul-Roc B, Bourget L, O'Connor-McCourt M. Differential sensitivity of A549 non-small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors. Cancer Biol Ther. 2008 Apr;7(4):557-68. Epub 2008 Jan 7. PubMed PMID: 18296914. 10: Matsuo M, Sakurai H, Saiki I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther. 2003 Jun;2(6):557-61. PubMed PMID: 12813135.

View History

MU-UNMC-2

MU-UNMC-2